+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Respiratory Syncytial Virus Treatment Market by Product Type (Antiviral Drugs, Monoclonal Antibodies, Vaccines), Indication (Prophylactic Use, Therapeutic Use), Age Group, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Human Respiratory Syncytial Virus Treatment Market by Product Type (Antiviral Drugs, Monoclonal Antibodies, Vaccines), Indication (Prophylactic Use, Therapeutic Use), Age Group, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Human Respiratory Syncytial Virus Treatment Market by Product Type (Antiviral Drugs, Monoclonal Antibodies, Vaccines), Indication (Prophylactic Use, Therapeutic Use), Age Group, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6133822
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Human respiratory syncytial virus (RSV) represents a leading cause of respiratory illness in vulnerable populations, particularly infants, the elderly and immunocompromised individuals. Each year, substantial clinical and economic burdens arise from RSV-related hospitalizations, long-term care requirements and outpatient interventions. Despite decades of research, effective prophylactic and therapeutic options have only recently begun to emerge, underscoring both the urgency and complexity of this public health challenge.

The current therapeutic landscape is undergoing a rapid transformation, characterized by the advent of novel antiviral agents, targeted monoclonal antibodies and promising vaccine candidates. Advances in molecular biology have enabled the development of RNA interference therapies and small-molecule antivirals designed to disrupt viral replication, while innovations in antibody engineering are yielding fully human and humanized immunotherapies with improved safety profiles. Concurrently, live attenuated and recombinant vaccines are progressing through clinical evaluation, offering potential preventative solutions for high-risk cohorts.

This executive summary distills pivotal insights from extensive research, including landscape shifts, policy implications, market segmentation, regional dynamics and competitive analysis. By weaving together these dimensions, decision-makers will gain a clear, actionable view of the evolving RSV treatment arena and be armed with strategic recommendations to inform investment, development and commercialization choices.

Unraveling Transformative Breakthroughs and Paradigm Shifts that Are Redefining the Human Respiratory Syncytial Virus Treatment Landscape

Historically, RSV treatment options were limited, often relying on supportive care and off-label therapies with modest effectiveness. As a result, the medical community has long awaited targeted interventions that can reduce hospitalization rates and improve patient outcomes. A confluence of scientific breakthroughs and regulatory milestones has now set the stage for a transformative era in RSV management.

The introduction of RNA interference platforms and small-molecule antivirals has created a new paradigm in directly inhibiting viral replication. Parallel progress in monoclonal antibody engineering has culminated in candidates offering extended half-lives and enhanced neutralization capabilities, particularly within fully human and humanized constructs. Vaccine research has similarly gained momentum, with both live attenuated and recombinant formulations advancing in clinical trials, signaling the potential for broad-based prophylactic strategies.

Looking ahead, integration of real-world evidence and adaptive regulatory pathways will further accelerate innovation. Strategic collaborations between biopharmaceutical companies, academic institutions and public health agencies are already fostering robust pipelines. As these initiatives mature, they promise to elevate standard-of-care treatments and expand access across diverse patient populations, ultimately reshaping the landscape of RSV prevention and therapy.

Evaluating the Cumulative Impact of United States Tariffs in 2025 on Supply Chains Pricing and Patient Access for Respiratory Syncytial Virus Treatments

In 2025, newly implemented United States tariffs targeting pharmaceutical imports have introduced additional cost pressures across multiple segments of the healthcare supply chain. These measures, intended to bolster domestic manufacturing, have inadvertently increased the landed cost of key active pharmaceutical ingredients and finished product imports, creating a ripple effect that extends from raw material sourcing to final distribution.

As drug developers and distributors adapt to elevated tariff burdens, strategies such as localized contract manufacturing and renegotiated supplier agreements are gaining prominence. Pricing departments are recalibrating wholesale acquisition costs to absorb higher import duties, while payers and providers are evaluating reimbursement models that can mitigate patient out-of-pocket expenses. The combined impact of these dynamics may influence formulary placements and access pathways for advanced antivirals, monoclonal antibodies and vaccine products.

Looking forward, industry participants are exploring tariff classification appeals and leveraging free trade zone mechanisms to optimize cost efficiencies. Proactive supply-chain diversification, including nearshoring and dual-sourcing strategies, will play a critical role in maintaining product availability and managing price resilience, ensuring that therapeutic innovations remain accessible to the populations most at risk.

Uncovering Critical Segmentation Insights Across Product Type Indication Age Group End User and Distribution Channel Dimensions Shaping RSV Treatment Strategies

The market for RSV therapies can be examined through multiple lenses that together paint a comprehensive segmentation picture. By product type, the universe encompasses antiviral drugs, dividing into RNA interference modalities and small-molecule agents; monoclonal antibodies, further categorized into fully human and humanized formats; and vaccine candidates classified as either live attenuated or recombinant. Each class exhibits distinct development challenges, safety considerations and administration protocols.

Indication segmentation reveals two primary application categories: prophylactic use and therapeutic intervention. In the prophylactic sphere, special focus falls on elderly individuals, high-risk infants and immunocompromised patients, each subgroup presenting unique immune response profiles and dosing requirements. Therapeutic usage is stratified by disease severity, ranging from mild upper respiratory symptoms to moderate hospitalized cases and severe respiratory distress necessitating intensive care support.

Age-based segmentation further refines the analysis, delineating adult populations aged 18 to 64, geriatric groups aged 65 and above and pediatric cohorts that include those two to twelve years old as well as children under two years. Differential efficacy, safety and dosing regimens across these age segments guide targeted clinical development and market rollout strategies.

End-user segmentation spans clinics, hospitals and research institutes. Clinics encompass both long-term care facilities and outpatient settings, while hospitals are split between private and public entities; research institutes comprise government and private organizations. Distribution channels are equally varied, spanning hospital pharmacies, online retail pharmacies and traditional retail outlets, each offering distinct access pathways and patient engagement opportunities.

Delineating Regional Dynamics and Distinctive Drivers Across the Americas Europe Middle East Africa and Asia Pacific Informing RSV Treatment Adoption Trends

In the Americas, evolving reimbursement frameworks and high hospitalization costs have spurred adoption of monoclonal antibody prophylaxis among high-risk infants, with payer collaborations driving greater coverage. At the same time, expansion of clinical trial networks throughout North and South America is strengthening the evidence base for emerging antivirals and vaccine candidates, facilitating accelerated regulatory review processes.

Within Europe, the Middle East and Africa, heterogeneous healthcare systems present both challenges and opportunities. In Western Europe, well established pharmacovigilance infrastructures support post-marketing surveillance for newly approved RSV therapies, while market access hurdles persist in parts of the Middle East and Africa. Governments in the region are actively exploring public-private partnerships to bolster local manufacturing capabilities, aiming to reduce import dependencies and enhance treatment availability.

The Asia-Pacific region is characterized by rapid investments in healthcare infrastructure and an expanding focus on vaccine-preventable diseases. Countries such as Japan and Australia have prioritized RSV immunization strategies for elderly cohorts, whereas emerging markets across Southeast Asia and India are accelerating clinical evaluations of next-generation antivirals. Regulatory harmonization efforts, including mutual recognition agreements, are streamlining approval timelines and supporting broader patient access.

Highlighting Leading Biopharmaceutical Innovators and Strategic Collaborations Driving Breakthroughs in Respiratory Syncytial Virus Treatment Partnerships

Leading biopharmaceutical companies are at the forefront of RSV innovation, harnessing proprietary RNA interference platforms and advanced antibody engineering capabilities. Strategic licensing deals have enabled large manufacturers to augment their pipelines with promising small-molecule antivirals and recombinant vaccine technologies sourced from pioneering biotechnology firms. These collaborations are critical in sharing development risk and expediting global market entry.

In parallel, joint ventures between academic research institutes and industry partners have fostered next-generation vaccine platforms, combining live attenuated constructs with novel adjuvants to enhance immunogenicity. Cross-border alliances are also emerging to facilitate access in low- and middle-income countries, where co-development agreements ensure affordability while safeguarding intellectual property. Collectively, these company-level maneuvers underscore a dynamic ecosystem of innovation, strategic alliances and competitive positioning that will shape the future of RSV treatment.

Providing Actionable Recommendations to Accelerate Innovation Partnerships and Commercial Breakthroughs in Respiratory Syncytial Virus Treatment

Industry leaders should prioritize integrated development roadmaps that align early-stage research with anticipated regulatory requirements, ensuring that novel RSV interventions meet evolving safety and efficacy standards. Investing in collaborative platforms that bring together academia, regulators and patient advocacy groups will foster transparent data sharing and expedite clinical validation processes.

From a commercialization perspective, forging partnerships with regional distribution networks and engaging payers early in pricing discussions will enhance market access and reimbursement confidence. It is equally important to implement flexible manufacturing strategies, including modular production units and dual-sourcing agreements, to mitigate tariff-related disruptions and supply-chain bottlenecks. By adopting a holistic approach that spans R&D, regulatory engagement, manufacturing resilience and market access planning, decision-makers can position their organizations to lead in the rapidly evolving RSV treatment domain.

Detailing a Rigorous Methodology Leveraging Stakeholder Interviews Data Triangulation and Analytical Frameworks to Derive RSV Treatment Insights

The research underpinning this analysis employed a rigorous methodology combining qualitative and quantitative techniques. Primary data were collected through in-depth interviews with key opinion leaders, including clinicians, virologists and payers, to obtain nuanced perspectives on unmet needs, competitive dynamics and emerging treatment modalities. These insights were complemented by extensive secondary research, drawing on peer-reviewed publications, clinical trial registries and regulatory filings to validate key findings.

Data triangulation was conducted to ensure consistency and reliability, cross-referencing primary insights with company press releases, patent landscapes and government health reports. Analytical frameworks were applied to segment the market by product type, indication, age group, end user and distribution channel, enabling granular assessment of growth drivers and potential obstacles. The result is a comprehensive, evidence-based view of the RSV treatment landscape designed to support informed strategic decision-making.

Synthesizing Key Insights and Strategic Implications to Guide Stakeholders in Advancing Efficacy and Access in Respiratory Syncytial Virus Treatment

This executive summary has synthesized critical facets of the human respiratory syncytial virus treatment landscape, from groundbreaking therapeutic innovations and tariff impacts to segmentation nuances and regional dynamics. By examining the interplay of scientific advances, policy shifts and market forces, stakeholders can appreciate the multifaceted nature of RSV prevention and therapy.

Armed with these insights, decision-makers are better positioned to craft strategies that optimize clinical development pathways, enhance patient access and drive commercial success. The synthesis of segmentation analysis, company-level collaborations and actionable recommendations provides a roadmap for navigating the complexities of this rapidly evolving field. Ultimately, a coordinated approach that integrates research excellence, strategic partnerships and adaptive market strategies will be pivotal in improving outcomes for those most vulnerable to RSV.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Antiviral Drugs
      • Rna Interference
      • Small Molecule
    • Monoclonal Antibodies
      • Fully Human
      • Humanized
    • Vaccines
      • Live Attenuated
      • Recombinant
  • Indication
    • Prophylactic Use
      • Elderly
      • High-Risk Infants
      • Immunocompromised
    • Therapeutic Use
      • Mild
      • Moderate
      • Severe
  • Age Group
    • Adult
      • 18 To 64 Years
    • Geriatric
      • 65 Years And Above
    • Pediatric
      • 2 To 12 Years
      • Under 2 Years
  • End User
    • Clinics
      • Long-Term Care Facilities
      • Outpatient Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Research Institutes
      • Government Research Institutes
      • Private Research Institutes
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AstraZeneca PLC
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Gilead Sciences, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of long-acting monoclonal antibody prophylaxis for high-risk infant populations beyond neonatal phase
5.2. Integration of maternal RSV immunization programs to curb infant hospitalization rates
5.3. Development of small molecule RSV inhibitors targeting viral fusion protein sites resistant to existing therapies
5.4. Rising adoption of combination antiviral and immune-modulatory treatment regimens in severe RSV cases
5.5. Growth in point-of-care diagnostics enabling early RSV detection and timely therapeutic intervention
5.6. Pipeline acceleration of next generation live attenuated RSV vaccines with enhanced mucosal immunity profiles
5.7. Strategic collaborations between biotech firms and academic institutions for RSV drug discovery and clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Respiratory Syncytial Virus Treatment Market, by Product Type
8.1. Introduction
8.2. Antiviral Drugs
8.2.1. Rna Interference
8.2.2. Small Molecule
8.3. Monoclonal Antibodies
8.3.1. Fully Human
8.3.2. Humanized
8.4. Vaccines
8.4.1. Live Attenuated
8.4.2. Recombinant
9. Human Respiratory Syncytial Virus Treatment Market, by Indication
9.1. Introduction
9.2. Prophylactic Use
9.2.1. Elderly
9.2.2. High-Risk Infants
9.2.3. Immunocompromised
9.3. Therapeutic Use
9.3.1. Mild
9.3.2. Moderate
9.3.3. Severe
10. Human Respiratory Syncytial Virus Treatment Market, by Age Group
10.1. Introduction
10.2. Adult
10.2.1. 18 To 64 Years
10.3. Geriatric
10.3.1. 65 Years And Above
10.4. Pediatric
10.4.1. 2 To 12 Years
10.4.2. Under 2 Years
11. Human Respiratory Syncytial Virus Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Long-Term Care Facilities
11.2.2. Outpatient Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Research Institutes
11.4.1. Government Research Institutes
11.4.2. Private Research Institutes
12. Human Respiratory Syncytial Virus Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Human Respiratory Syncytial Virus Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Respiratory Syncytial Virus Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Pfizer Inc.
16.3.3. GlaxoSmithKline plc
16.3.4. Moderna, Inc.
16.3.5. Johnson & Johnson
16.3.6. Sanofi S.A.
16.3.7. Merck & Co., Inc.
16.3.8. Novavax, Inc.
16.3.9. Bavarian Nordic A/S
16.3.10. Gilead Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHAI
FIGURE 26. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HIGH-RISK INFANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HIGH-RISK INFANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 18 TO 64 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 18 TO 64 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 65 YEARS AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 2 TO 12 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY 2 TO 12 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY UNDER 2 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY UNDER 2 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 181. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 184. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 185. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 186. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 187. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 188. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 189. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 192. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 193. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 194. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 195. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 196. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 197. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 198. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 199. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 200. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 201. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 202. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 203. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 206. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 207. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 208. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 209. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 210. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 211. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. CANADA HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 225. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 228. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 231. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 232. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 233. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 234. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 235. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 242. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 243. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. MEXICO HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PROPHYLACTIC USE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY THERAPEUTIC USE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY GERIATRIC, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL HUMAN RESPIRATORY SYNCYTIAL VIRUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL HUMAN RESP

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human Respiratory Syncytial Virus Treatment market report include:
  • AstraZeneca PLC
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Gilead Sciences, Inc.

Related Topics

Related Reports

Respiratory Syncytial Virus Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Respiratory Syncytial Virus Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 82 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) - Market Insight, Epidemiology And Market Forecast - 2032 - Product Image

Respiratory Syncytial Virus (RSV) - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • 164 Pages
  • Global
From
Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type (Monoclonal Antibody, Small Molecule Therapy, Vaccine), Route Of Administration (Intramuscular, Intravenous, Oral), Patient Type, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type (Monoclonal Antibody, Small Molecule Therapy, Vaccine), Route Of Administration (Intramuscular, Intravenous, Oral), Patient Type, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Image

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • 307 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.